PL2940014T3 - Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna - Google Patents

Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna

Info

Publication number
PL2940014T3
PL2940014T3 PL13867650T PL13867650T PL2940014T3 PL 2940014 T3 PL2940014 T3 PL 2940014T3 PL 13867650 T PL13867650 T PL 13867650T PL 13867650 T PL13867650 T PL 13867650T PL 2940014 T3 PL2940014 T3 PL 2940014T3
Authority
PL
Poland
Prior art keywords
suppressant
isoindole
dihydro
derivative
pharmaceutical composition
Prior art date
Application number
PL13867650T
Other languages
English (en)
Polish (pl)
Inventor
Yong Rae Hong
Jeong Eun Na
Im Sook MIN
Hyun Ju Cha
Sool Ki Kwon
Seonggu Ro
Joong Myung Cho
Original Assignee
Crystalgenomics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystalgenomics, Inc. filed Critical Crystalgenomics, Inc.
Publication of PL2940014T3 publication Critical patent/PL2940014T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13867650T 2012-12-28 2013-12-26 Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna PL2940014T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261746980P 2012-12-28 2012-12-28
EP13867650.7A EP2940014B1 (en) 2012-12-28 2013-12-26 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same
PCT/KR2013/012204 WO2014104757A1 (ko) 2012-12-28 2013-12-26 Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물

Publications (1)

Publication Number Publication Date
PL2940014T3 true PL2940014T3 (pl) 2019-03-29

Family

ID=51021712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13867650T PL2940014T3 (pl) 2012-12-28 2013-12-26 Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna

Country Status (15)

Country Link
US (4) US9758508B2 (Direct)
EP (2) EP3428161B1 (Direct)
JP (2) JP6325573B2 (Direct)
KR (1) KR102009163B1 (Direct)
CN (1) CN104995184B (Direct)
AU (3) AU2013371146C1 (Direct)
BR (1) BR112015015477B1 (Direct)
CA (1) CA2896711C (Direct)
DK (1) DK2940014T3 (Direct)
ES (2) ES2696700T3 (Direct)
MX (2) MX386542B (Direct)
PL (1) PL2940014T3 (Direct)
PT (1) PT2940014T (Direct)
RU (2) RU2018138028A (Direct)
WO (1) WO2014104757A1 (Direct)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
AU2013371146C1 (en) * 2012-12-28 2019-01-17 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド RETキナーゼ阻害物質としての置換ピラゾロ[1,5−a]ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
MX2019009954A (es) * 2017-02-21 2019-12-19 Aptose Biosciences Inc Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas.
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022509257A (ja) * 2018-11-30 2022-01-20 アプトース バイオサイエンシズ インコーポレイテッド 2,3-ジヒドロ-イソインドール-1-オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022150801A1 (en) * 2021-01-05 2022-07-14 Sumitomo Pharma Oncology, Inc. Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor
EP4301756A4 (en) * 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0208891A (pt) * 2001-04-12 2004-04-20 Hoffmann La Roche Derivados de dihidro-benzo[b]-[1,4]diazepin-2-ona como antagonistas de mglur2 ii
WO2004108672A1 (en) * 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
CN101163675A (zh) * 2005-04-19 2008-04-16 协和发酵工业株式会社 含氮杂环化合物
WO2007047646A2 (en) * 2005-10-14 2007-04-26 Janssen Pharmaceutica, N.V. Substituted dihydro-isoindolones useful in treating kinase disorders
EP1998777A1 (en) * 2006-03-20 2008-12-10 F. Hoffmann-La Roche AG Methods of inhibiting btk and syk protein kinases
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
WO2012014017A1 (en) 2010-07-30 2012-02-02 Poly Medicure Limited Catheter introducer
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
AU2013371146C1 (en) * 2012-12-28 2019-01-17 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase

Also Published As

Publication number Publication date
JP2018109069A (ja) 2018-07-12
EP2940014B1 (en) 2018-09-26
JP6596537B2 (ja) 2019-10-23
US20150336934A1 (en) 2015-11-26
US20210009565A1 (en) 2021-01-14
US20170362205A1 (en) 2017-12-21
HK1259355A1 (en) 2019-11-29
US10604508B2 (en) 2020-03-31
EP3428161A1 (en) 2019-01-16
ES2696700T3 (es) 2019-01-17
ES2929906T3 (es) 2022-12-02
EP3428161B1 (en) 2022-09-07
US9758508B2 (en) 2017-09-12
WO2014104757A1 (ko) 2014-07-03
KR102009163B1 (ko) 2019-08-09
MX2015008396A (es) 2016-04-15
AU2018214134B2 (en) 2020-03-12
AU2013371146A1 (en) 2015-07-16
CA2896711C (en) 2019-12-31
JP6325573B2 (ja) 2018-05-16
AU2013371146B2 (en) 2018-05-10
KR20160058720A (ko) 2016-05-25
PT2940014T (pt) 2018-11-28
AU2013371146C1 (en) 2019-01-17
EP2940014A4 (en) 2016-06-22
EP2940014A1 (en) 2015-11-04
RU2015124381A (ru) 2017-02-01
RU2671847C2 (ru) 2018-11-07
BR112015015477A2 (pt) 2017-07-11
BR112015015477B1 (pt) 2022-07-12
MX2021011563A (es) 2022-10-10
AU2020201431B2 (en) 2021-07-22
AU2018214134A1 (en) 2018-08-30
JP2016504351A (ja) 2016-02-12
DK2940014T3 (en) 2018-12-10
CN104995184A (zh) 2015-10-21
CA2896711A1 (en) 2014-07-03
US11230539B2 (en) 2022-01-25
CN104995184B (zh) 2018-01-02
AU2020201431A1 (en) 2020-03-19
MX386542B (es) 2025-03-18
RU2018138028A (ru) 2019-03-21
US20220380346A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
PL2940014T3 (pl) Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna
ZA201406233B (en) Pharmaceutical composition and administration thereof
IL237839A0 (en) History of hydropyrrolopyrrole, their preparation and pharmaceutical preparations containing them
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL235767A (en) Preserved pyrolidines, pharmaceuticals containing them and their uses
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
IL237072B (en) History of isoquinolinone, their preparation and pharmaceutical preparations containing them
IL235414A (en) The history of pyrolotriazinone, their preparation and their pharmaceutical preparations
IL237073A (en) History of pyridopyrimidine, their preparation and their pharmaceutical preparations
IL238060B (en) 2-aminopyridine derivatives, their preparation and pharmaceutical compositions containing them
IL238825A0 (en) The history of heterocyclics, their preparation and pharmaceutical preparations containing them
IL232035A (en) These heterocyclic compounds, these compounds as a medicine and a pharmaceutical composition containing them
ZA201505318B (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
IL233602A (en) The history of benzamide, their preparation and their pharmaceutical preparations
IL233529A (en) 1, 5-Naphthyridine derivatives and lactose-containing pharmacological preparations
IL232577A (en) History of morpholinylbenzotriazine, their preparation and their pharmaceutical preparations
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
IL239054B (en) History of azaquinazoline carboxamide, their preparation and pharmaceutical preparations containing them
IL235955A0 (en) The history of benzothiophene, their preparation and pharmaceutical preparations containing them
IL246298A0 (en) History of piperidine, their preparation and pharmaceutical preparations containing them
IL231699A (en) History of benzyl piperidine, their preparation and their pharmaceutical preparations
IL228705A (en) Derivatives of Reliable Phenoxy-Ethyl, Pharmaceutical Preparations Containing and Using Them